DrugPatentWatch Database Preview
Drugs in Development Information for LDK378
» See Plans and Pricing
What is the drug development status for LDK378?
LDK378 is an investigational drug.
There have been 29 clinical trials for LDK378.
The most recent clinical trial was a Phase 2 trial, which was initiated on December 1st 2015.
The most common disease conditions in clinical trials are Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, and Lymphoma. The leading clinical trial sponsors are Novartis Pharmaceuticals, National Cancer Institute (NCI), and Novartis.
There are thirty-nine US patents protecting this investigational drug and seven hundred and seventy-nine international patents.
Summary for LDK378
| US Patents | 39 |
| International Patents | 779 |
| US Patent Applications | 95 |
| WIPO Patent Applications | 844 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2015-12-01) |
| Vendors | 75 |
Recent Clinical Trials for LDK378
| Title | Sponsor | Phase |
|---|---|---|
| Biomarker/ALK Inhibitor Combinations in Treating Patients With Stage IV ALK Positive Non-Small Cell Lung Cancer (The NCI-NRG ALK Master Protocol) | National Cancer Institute (NCI) | Phase 2 |
| A Study of LDK378 in Patients With Non-small Cell Lung Cancer Harboring ROS1 Rearrangement | Yonsei University | Phase 2 |
| Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell Lymphoma | National Cancer Institute (NCI) | Phase 1/Phase 2 |
Clinical Trial Summary for LDK378
Top disease conditions for LDK378
Top clinical trial sponsors for LDK378
US Patents for LDK378
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| LDK378 | Start Trial | Polycyclic inhibitor of anaplastic lymphoma kinase | XUANZHU PHARMA CO., LTD. (Jinan, Shandong Province, CN) | Start Trial |
| LDK378 | Start Trial | Hydrate of 2-isopropoxy-5-methyl-4-(piperidin-4-yl) aniline dihydrochloride, preparation method and use of the same | 2Y-CHEM, LTD. (Shanghai, CN) | Start Trial |
| LDK378 | Start Trial | Inhibitors of ACK1/TNK2 tyrosine kinase | H. Lee Moffitt Cancer Center and Research Institute, Inc. (Tampa, FL) | Start Trial |
| LDK378 | Start Trial | Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptor | Novartis AG (Basel, CH) The Trustees of the University of Pennsylvania (Philadelphia, PA) | Start Trial |
| LDK378 | Start Trial | CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell | Novartis AG (Basel, CH) The Trustees of the University of Pennsylvania (Philadelphia, PA) | Start Trial |
| LDK378 | Start Trial | Treatment of cancer using anti-CD19 Chimeric Antigen Receptor | The Trustees of the University of Pennsylvania (Philadelphia, PA) Novartis AG (Basel, CH) | Start Trial |
| LDK378 | Start Trial | Compositions and methods for activating "stimulator of interferon gene"--dependent signalling | ADURO BIOTECH, INC. (Berkeley, CA) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for LDK378
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| LDK378 | China | CN107108586 | 2034-09-29 | Start Trial |
| LDK378 | European Patent Office | EP3202765 | 2034-09-29 | Start Trial |
| LDK378 | Japan | JP2017530139 | 2034-09-29 | Start Trial |
| LDK378 | Japan | JP6554538 | 2034-09-29 | Start Trial |
| LDK378 | South Korea | KR101909404 | 2034-09-29 | Start Trial |
| LDK378 | South Korea | KR20170055555 | 2034-09-29 | Start Trial |
| LDK378 | World Intellectual Property Organization (WIPO) | WO2016050171 | 2034-09-29 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
